Categories: News

BBS-Bioactive Bone Substitutes Oyj – Managers’ Transactions – Jarmo Halonen

BBS-Bioactive Bone Substitutes Plc, Company announcement, management transactions, 7 August 2023 at 16.00 (EEST)

BBS-Bioactive Bone Substitutes Oyj – Managers’ Transactions – Jarmo Halonen

This Company announcement contains information on the following management transactions:

  • Subscription of shares with warrants (TO1) 24 and 25 November 2022
  • Discposal of shares on 22 December 2022
  • Subscription of shares in share issues on 21 and 29 June 2023

____________________________________________

Person subject to the notification requirement

Name: Halonen Jarmo

Position: Member of the Board/Deputy member

Issuer: BBS Bioactive Bone Substitutes Oyj

LEI: 743700BYSBP0PCR6N767

Notification type: INITIAL NOTIFICATION

Reference number: 743700BYSBP0PCR6N767_20230804145820_11

____________________________________________

Transaction date: 2022-11-24

Venue not applicable

Instrument type: SHARE

ISIN: FI4000260583

Nature of the transaction: SUBSCRIPTION

(X) Linked to stock option programme

Transaction details

(1): Volume: 751 Unit price: 0.92 EUR

Aggregated transactions

(1): Volume: 751 Volume weighted average price: 0.92 EUR

____________________________________________

Transaction date: 2022-11-25

Venue not applicable

Instrument type: SHARE

ISIN: FI4000260583

Nature of the transaction: SUBSCRIPTION

(X) Linked to stock option programme

Transaction details

(1): Volume: 843 Unit price: 0.92 EUR

(2): Volume: 599 Unit price: 0.92 EUR

Aggregated transactions

(2): Volume: 1,442 Volume weighted average price: 0.92 EUR

____________________________________________

Transaction date: 2022-12-22

Venue: FIRST NORTH FINLAND (FNFI)

Instrument type: SHARE

ISIN: FI4000260583

Nature of the transaction: DISPOSAL

Transaction details

(1): Volume: 600 Unit price: 1.2 EUR

(2): Volume: 650 Unit price: 1.195 EUR

Aggregated transactions

(2): Volume: 1,250 Volume weighted average price: 1.1974 EUR

____________________________________________

Transaction date: 2023-06-21

Venue not applicable

Instrument type: SHARE

ISIN: FI4000260583

Nature of the transaction: SUBSCRIPTION

Transaction details

(1): Volume: 4,191 Unit price: 0.5 EUR

Aggregated transactions

(1): Volume: 4,191 Volume weighted average price: 0.5 EUR

____________________________________________

Transaction date: 2023-06-29

Venue not applicable

Instrument type: SHARE

ISIN: FI4000260583

Nature of the transaction: SUBSCRIPTION

Transaction details

(1): Volume: 3,600 Unit price: 0.55 EUR

(2): Volume: 6,400 Unit price: 0.55 EUR

Aggregated transactions

(2): Volume: 10,000 Volume weighted average price: 0.55 EUR

Contact information:

Ilkka Kangasniemi, CEO
040 708 0307
ilkka.kangasniemi@bbs-artebone.fi

Staff

Recent Posts

Vent Creativity Appoints Paul Abrams as Vice President of Sales to Lead Commercial Growth

NEW YORK--(BUSINESS WIRE)--Vent Creativity, a medical technology company advancing AI-enabled surgical planning, today announced the…

14 hours ago

AEON Clinic Announces Next Generation Medicine Congress 2026 Event: A Global Convergence on Human Longevity in Dubai

AEON Clinic Elevates Dubai to Global Hub for Longevity Science, A Definitive Four-Day Summit Defining…

14 hours ago

AI-Era Position Statement to Protect the Integrity of Healthcare, Technology, and Services Benchmarking published by Black Book Research

Black Book outlines an AI-era integrity architecture for healthcare benchmarking, instrumentation hardening, tiered verification, real-time…

2 days ago

New employee representative on the Board of Directors of Novo Nordisk A/S

Bagsværd, Denmark, 31 January 2026 – Thomas Rantzau, employee representative on the Board of Directors since…

2 days ago

Embers to Empowerment: The Womb Room Reopens in Govans, Expanding Community-Centered Perinatal Care After Hampden Fire

Baltimore, Maryland, Jan. 31, 2026 (GLOBE NEWSWIRE) -- After sustaining water damage during the massive…

2 days ago

Oxford Healthspan to Introduce New Primeadine® GF Powder Through a ‘Longevity Shot’ Experience During Grammy Week in Los Angeles

Science-Backed Spermidine Ritual Brings Cellular Renewal to a High-Performance Cultural Moment Primeadine Longevity Shot Primeadine…

2 days ago